Overview: CAPA, Corrective and Preventive Action, is a major element of cGMP compliance, and key source of regulatory problems.
How can companies allocate scarce resources to those activities that have the greatest impact to product quality / safety, minimize resources on minor issues, and still satisfy the regulatory agencies? Since the US FDA and the EU have repeatedly stated that the majority of quality and regulatory activities are or should be “risk based�, how can this be implemented under CAPA. Changing a company’s CAPA system to a true risk-based closed-loop system results in proper use of scarce resources to activities that have a higher payoff in terms of reduced liability, both civil and regulatory, and improved product function and safety.
Areas Covered in the Session:
FDA’s and EU’s Emphasis
QSIT for a strategic, systems analysis of CAPA and high risk concerns
How to use your Risk Management Tools (per Q9 and ISO 14971)
CAPA – a crucial series of risk-based lifecycle deliverables
Corrections and Risk
Corrective Action and Risk
Preventive Action and Risk
Closing the Loop
Management Review – tying it all together; taking it to the next level